Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Diabetes (type 2) - dapagliflozin: evaluation report

01       NICE’s response to comments on the Appraisal Consultation Document (ACD

02       Bristol Myers-Squibb and AstraZeneca

03       National Diabetes Nurses Consultant Group

04       Consultee comments on the ACD - Royal College of Nursing

05       Consultee comments on the ACD - Department of Health

06       Consultee comments on the ACD - NHS Middlesbrough

07       Consultee comments on the ACD - Commissioning Support Appraisals Service

08       Commentator comments on the ACD - Boehringer Ingelheim (including manufacturer’s                          response to model comments)

09       Commentator comments on the ACD - Eli Lilly

10       Commentator comments on the ACD - Merck Sharpe & Dohme

11       Commentator comments on the ACD - Novo Nordisk

12       Comments on the Appraisal Consultation Document received through the NICE website

13       Decision Support Unit report - March 2013

14       Evidence Review Group addendum - March 2013

15       Decision Support Unit report - April 2013